Historically, Trump's statements on reducing drug prices have led to increased volatility in the pharmaceutical industry. However, his latest plan to cut out middlemen and facilitate direct sales at the most favored nation price could lead to significant cost savings for consumers, potentially boosting the stock prices of companies that adopt this model. The plan may also lead to increased market confidence, as it could be seen as a pro-consumer move. On the other hand, pharmaceutical companies that rely heavily on middlemen for their revenue streams may see a negative impact. Overall, the plan has the potential to increase market volatility in the short term, but could lead to long-term gains for companies that adapt to the new pricing model. The plan's regulatory implications will be crucial in determining its success, and its impact on international trade will also be closely watched. Trump's stance on the pharmaceutical industry has been critical in the past, but this plan could be seen as a more conciliatory approach, potentially leading to increased cooperation between the industry and the government.